Welcome to CRISPR 2015 Oxford Symposium
CRISPR-cas systems are among the newest additions to gene editing and regulating tools, offering unlimited possibilities, with considerable potential in genetic medicine, agriculture, biotechnology and fundamental research. Thus, in principle, CRISPR-cas systems have application in targeting defective genes to cure hereditary disorders, improving crops and livestock, enhancing biotechnological production of proteins, enzymes and metabolites and in engineering model laboratory animals for a particular set of investigations.
We are delighted to announce our first CRISPR symposium at Oxford, which will be held on 23rd March at St Hilda’s College. This symposium will be one of the first international meetings at Oxford that will bring together the CRISPR community from both academia and industry to discuss and share new ideas and applications of CRISPR-cas systems in genome editing and engineering.
We welcome proposals for poster presentation, in particular on new applications and experimental design using CRISPR-cas. Please contact us on CRISPR@LPMHealthcare.com, if you have any questions.
The Symposium will be co-hosted with our 10th annual RNAi conference and exhibition, RNAi 2015.
Sigma-Aldrich CRISPR Technology Workshop – 24th March
Sigma-Aldrich are pleased to offer this half-day, fully-sponsored CRISPR Technology workshop on 24th March (morning). Registration for this workshop is free.
Sigma-Aldrich has an extensive long-term experience in developing technologies for Targeted Genome Editing. Since 2008 they have offered validated ZFN-based kits and are now leading the development of new CRISPR/Cas9 associated products and services.
During this Day 2 of the CRISPR 2015 Oxford Symposium, scientist from Sigma-Aldrich as well as specially invited UK-based researchers will present a series of CRISPR talks that will further enhance your knowledge on Targeted Genome Editing in general and on the CRISPR/Cas9 technology in particular.
Click here for workshop agenda.
CRISPR 2015 Agenda
10.30: Dr William Skarnes, PhD (Keynote address)
Senior Group Leader, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
Title: High-throughput genome engineering of human stem cells
11.00: Dr Qingzhou Ji, PhD
Principal Scientist, Sigma-Aldrich, USA
Title: Targeted histone acetylation and activation of endogenous genes using engineered ZF-p300 and CRISPR-p300
11.20: Dr Mark Behlke, PhD
Chief Scientific Officer, Integrated DNA Technologies, USA
Title: Co-transfection of synthetic RNA targeting oligos and Cas9 protein for CRISPR gene editing
11.40: Dr Annaleen Vermeulen, PhD
Senior Scientist, GE Healthcare/Dharmacon, CO, USA
Title: Systematic analysis of CRISPR-Cas9 mismatch tolerance reveals low levels of off-target activity using synthetic crRNA and tracrRNA
12.00: Dr Scott Brouilette, PhD
Sr. Marketing Technical Specialist, UK & Ireland, illumina Cambridge Ltd, UK
Title: NGS plus CRISPR: variant identification & validation simplified
12.20: Lunch, posters, networking, exhibition
13.20: Dr Graeme Doran, PhD
Director of Genomic Assays, Firefly BioWorks Inc, One Kendall Square, Cambridge, MA, USA
Title: Direct quantification of small nucleic acid delivery to tissues
13.30: Dr Benoit Giquel, PhD
Outreach Scientist Europe, Addgene, Cambridge, MA, USA
Title: CRISPR plasmid technology and trends: Data from Addgene’s Plasmid Repository
13.50: Dr Philip Webber, PhD
Dehns Patent and Trademark Attorneys, Willow Court, Oxford, UK
Title: Crispr: Patenting your inventions
14.10: Dr Tom Webb, PhD
Lecturer in Cardiovascular Genomics, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
Title: A CRISPR/Cas9 screen to identify genes required for telomere maintenance
14.30: Dr Jean-Paul Vincent, PhD, FMedSci, FRS
MRC National Institute for Medical Research, London, UK
Title: Genome modification in Drosophila with Cas9, homologous recombination and Phi31-mediated integration
14.50: Dr Joffrey Mianne, PhD
MRC Harwell, Harwell Science & Innovation Campus, Oxfordshire, UK
Title: Engineering mouse genome using CRISPR/Cas9
15.10: Refreshment break, networking, exhibition
15.50: Dr Bon-Kyoung Koo, PhD
Principal Investigator, The Wellcome Trust Centre for Stem Cell Research, University or Cambridge, UK
Title: Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients
16.10: Dr Robin Ketteler, PhD
MRC Laboratory of Molecular Cell Biology, University College London, UK
Title: CRISPR Edited Cell Lines For the Study of Autophagy
16.30: Dr Andrew Bassett, PhD
Postdoctoral Scientist, University of Oxford, UK
Title: Investigation of miRNA function using genome engineering
16.50: Dr Vlad Nekrasov, PhD
The Sainsbury Laboratory, Norwich Research Park, Norwich,UK
Title: Exploiting the CRISPR/Cas9 technology as a tool for targeted mutagenesis in plants
17.10: Dr Pantao Liu, PhD
The Wellcome Trust Sanger Institute, Hinxton, UK
Title: The CRISPR/Cas9 And TALES in gene expression regulation, genetic screens, and gene targeting in human iPS cells
Targeted genome editing with engineered endonucleases
Amna A Alotiby, Lucy C Fairclough, Ian Todd, Paddy J Tighe
MBTI Research Group, School of Life Sciences, University of Nottingham, Nottingham
Evidence from more than 700 genome editing experiments using CRISPR/Cas – lessons learned
Daniel H Lackner1, Paloma Guzzardo1, Richard Schobesberger1, Ana Lapao1, Philipp Hainzl1, Lilian Lohninger1, Sebastian MB Nijman2, Thijn R Brummelkamp3, Tilmann Bürckstümmer1
1Horizon Genomics, Campus Vienna Biocenter 5, 1030 Vienna, Austria
2Ludwig Cancer Research, Oxford Branch, Old Road Campus Research Building, Headington OXF, OX3 7DQ, UK
3Netherlands Cancer Institute (NKI), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Enhanced engineering success with optimized cell line screening procedure
Thibault Laurent, Aleksander Gontarczyk, Tim Scales, Jane Elliott, Holly M Astley, Chris E Lowe, Kyla Grimshaw
Horizon Discovery Group plc, Cambridge, UK
Using the CRISPR technology to develop cellular models of Hypertrophic Cardiomyopathy
Sandra B Martins, Teresa Carvalho, Rita M Almeida, Catarina Santos and Maria Carmo-Fonseca
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
CRISPRdirect: web-based tool for designing CRISPR/Cas guide RNA with reduced off-target sites
Yuki Naito1,2, Kimihiro Hino3, Kumiko Ui-Tei3, Hidemasa Bono1,2
1Database Center for Life Science (DBCLS), and
2National Institute of Genetics, Research Organization of Information and Systems, 1111 Yata, Mishima, Shizuoka 411-8540, Japan
3Department of Biological Sciences, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in a human primary cell phenotypic assay
Olaf Voets, Frans Tielen1, Edo Elstak, Julian Benschop, Max Grimbergen, Jan Stallen, Richard Janssen, Andre van Marle, Christian Essrich
Galapagos BV, Darwinweg 24, 2333 CR Leiden, The Netherlands
CRISPR 2015 Sponsors
Gold Sponsor and Exhibitor
Sigma-Aldrich is a global supplier of leading RNA interference (RNAi) tools including siRNA and the comprehensive MISSION® shRNA library through participation in The RNAi Consortium (TRC). As a key licensed supplier of siRNA and expert in high quality custom DNA and RNA oligonucleotide synthesis, our goal is to provide innovative products to meet your functional genomics and gene silencing research needs. The MISSION shRNA library of The RNAi Consortium, developed by the Broad Institute of MIT and Harvard, is a pre-cloned collection targeted against annotated human and mouse genes enabling scientists to elucidate gene function. For further details of the above products please visit www.sigma-aldrich.com.
Sigma-Aldrich, a leading Life Science and High Technology company focused on enhancing human health and safety, manufactures and distributes more than 200,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units – Research, Applied and SAFC Commercial – Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 37 countries, has more than 9,000 employees worldwide and had sales of $2.6 billion in 2012. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.
Silver Sponsor and Exhibitor
transOMIC technologies inc is a biotechnology company focused on providing the life science research market with innovative technologies and research tools to accelerate the quest towards elucidating the complexity of life and human disease. These research tools for gene manipulation provide investigators with standardized high-quality genes, RNAi tools for gene knockdown, CRISPR reagents for genome editing and delivery reagents for interrogating gene function.
Address: 601 Genome Way, Suite 1222, Huntsville, AL 35806, USA
Phone: 866-833-0712 Fax: 256-327-9515
Bronze Sponsor and Exhibitor
Takara Bio Europe and Clontech Laboratories are members of the Takara Bio Group, a leading supplier of tools for life scientists worldwide. Through our brand names TAKARA and CLONTECH we develop innovative technologies in the fields of Stem Cells and Epigenetics, Molecular and Cell Biology, and Gene/Protein Function. Key products include SMARTer™ cDNA synthesis kits for next generation sequencing, the innovative In-Fusion® HD Cloning Plus System, high performance PCR/qPCR reagents, Tet-regulated gene expression systems, Living Colors® Fluorescent Proteins, as well as a broad choice of viral vectors/particles and transduction tools.
Our recently launched Guide-it™ kits are excellent tools for genome engineering using CRISPR/Cas9 technology. The Guide-it™ portfolio includes kits for efficient in vitro production and screening of single guide RNAs (sgRNAs) as well as Mutation Detection and Indel Identification kits for monitoring the efficiency of genome editing.
Learn more on www.clontech.com/guide-it.
Bronze Sponsor and Exhibitor
Integrated DNA Technologies (IDT) is a leader in the manufacture and development of products for the research and diagnostic life science market. The largest supplier of custom nucleic acids in the world, IDT serves academic research, biotechnology, and pharmaceutical development communities.
IDT products support a wide variety of applications, including next generation sequencing (NGS), DNA amplification, SNP detection, microarray analysis, expression profiling, gene quantification, and synthetic biology. Platform-independent NGS products and services are available in addition to DNA and RNA oligonucleotides, qPCR assays, siRNA duplexes, and custom gene synthesis. Individually-synthesized xGen™ Lockdown™ Probes enable improved target capture. IDT also manufactures custom adaptors, fusion primers, Molecular Identifier tags (MIDs), and other workflow oligonucleotides for NGS. A TruGrade™ processing service is also available to reduce oligonucleotide crosstalk during multiplex NGS.
Serving over 80,000 life sciences researchers, IDT is widely recognized as the industry leader in custom oligonucleotide manufacture due to its unique capabilities. IDT pioneered the use of high throughput quality control (QC) methods and is the only oligonucleotide manufacturer to offer purity guarantees and 100% QC. Every oligonucleotide is analyzed by mass spectrometry and purified oligonucleotides receive further analysis by CE and HPLC. The company maintains an engineering division dedicated to advancing synthesis, processing technology, and automation. An in-house machine shop provides rapid prototyping and custom part design/control. Additionally, IDT offers unrivalled customer support, receiving approximately 100,000 calls annually with an average wait time of only 8 seconds.
A dedicated GMP manufacturing facility for molecular diagnostics provides oligonucleotides for In Vitro Diagnostic Devices (IVDs) or Analyte Specific Reagents (ASRs) for Laboratory-Developed Tests (LDTs). This manufacturing process is customer-defined and controlled, and facilitates progression from research to commercialization.
Lonza provides the pharma market with the tools that life-science researchers use to develop and test therapeutics, beginning with basic research stages on to the final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research to quality control tests and software that ensures product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies. The company delivers physiologically relevant cell biology solutions and complete solutions for rapid microbiology.
Lonza Cologne GmbH, Nattermannallee 1, Koeln, 50829, Germany
Phone: +49-221-99199-0, Fax: +49-221-99199-111